|
[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
|
|
[2] OMATA M,CHENG AL,KOKUDO N,et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma:A 2017 update[J]. Hepatol Int,2017,11(4):317-370.
|
|
[3] IRSHAD M,MANKOTIA DS,IRSHAD K. An insight into the diagnosis and pathogenesis of hepatitis C virus infection[J].World J Gastroenterol,2013,19(44):7896-7909.
|
|
[4] FELD JJ,JACOBSON IM,HZODE C,et al. Sofosbuvir and velpatasvir for HCV genotype 1,2,4,5,and 6 infection[J].N Engl J Med,2015,373(27):2599-2607.
|
|
[5] REIG M,MARIO Z,PERELLC,et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy[J]. J Hepatol,2016,65(4):719-726.
|
|
[6] ROBERT SB Jr. The possible association between DAA treatment for HCV infection and HCC recurrence[J]. Gastroenterol Hepatol(N Y),2016,12(12):776-779.
|
|
[7] CONTI F,BUONFIGLIOLI F,SCUTERI A,et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals[J]. J Hepatol,2016,65(4):727-733.
|
|
[8] WARZYSZYN'SKA K,JONAS M,WASIAK D,et al. Accelerated hepatocellular carcinoma recurrence rate after postoperative direct-acting antivirals treatment-preliminary report[J].Clin Exp Hepatol,2017,3(4):194-197.
|
|
[9] TORRES HA,VAUTHEY JN,ECONOMIDES MP,et al. Hepatocellular carcinoma recurrence after treatment with directacting antivirals:First,do no harm by withdrawing treatment[J]. J Hepatol,2016,65(4):862-864.
|
|
[10] ANRS collaborative study group on hepatocellular carcinoma(ANRS CO22 HEPATHER,CO12 Cir Vir and CO23 CUPILT cohorts). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma:Data from three ANRS cohorts[J]. J Hepatol,2016,65(4):734-740.
|
|
[11] VIRLOGEUX V,PRADAT P,HARTIG-LAVIE K,et al. Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C[J]. Liver Int,2017,37(8):1122-1127.
|
|
[12] IKEDA K,KAWAMURA Y,KOBAYASHI M,et al. Direct-acting antivirals decreased tumor recurrence after initial treatment of hepatitis C virus-related hepatocellular carcinoma[J]. Dig Dis Sci,2017,62(10):2932-2942.
|
|
[13] HUANG AC,MEHTA N,DODGE JL,et al. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout[J]. Hepatology,2018,68(2):449-461.
|
|
[14] CABIBBO G,CELSA C,CALVARUSO V,et al. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients[J]. J Hepatol,2019,71(2):265-273.
|
|
[15] CHI CT,CHEN CY,SU CW,et al. Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan[J]. J Microbiol Immunol Infect,2019.[Online ahead of print]
|
|
[16] NISHIBATAKE KINOSHITA M,MINAMI T,TATEISHI R,et al.Impact of direct-acting antivirals on early recurrence of HCV-related HCC:Comparison with interferon-based therapy[J]. J Hepatol,2019,70(1):78-86.
|
|
[17] IMAI K,TAKAI K,HANAI T,et al. Sustained virological response by direct-acting antivirals reduces the recurrence risk of hepatitis C-related hepatocellular carcinoma after curative treatment[J]. Mol Clin Oncol,2020,12(2):111-116.
|
|
[18] KUO YH,WANG JH,CHANG KC,et al. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment[J]. Invest New Drugs,2020,38(1):202-210.
|
|
[19] MIUMA S,MIYAMOTO J,TAURA N,et al. Influence of interferon-free direct-acting antiviral therapy on primary hepatocellular carcinoma recurrence:A landmark time analysis and time-dependent extended cox proportional hazards model analysis[J]. Intern Med,2020,59(7):901-907.
|
|
[20] CAMMC,CABIBBO G,CRAXA. Direct antiviral agents and risk for HCC early recurrence:Much ado about nothing[J]. J Hepatol,2016,65(4):861-862.
|
|
[21] BLANCO JR,RIVERO-JUREZ A. The risk of hepatocellular carcinoma after sustained virological response in patients treated with the new direct-acting antiviral drugs:Should we be worry about it?[J]. Expert Rev Anti Infect Ther,2016,14(11):993-996.
|
|
[22] YANO H,IEMURA A,HARAMAKI M,et al. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines[J]. Hepatology,1999,29(6):1708-1717.
|
|
[23] NAKAMURA M,NAGANO H,SAKON M,et al. Role of the Fas/Fas L pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro[J]. J Hepatol,2007,46(1):77-88.
|
|
[24] GEORGE PM,BADIGER R,ALAZAWI W,et al. Pharmacology and therapeutic potential of interferons[J]. Pharmacol Ther,2012,135(1):44-53.
|
|
[25] MIYAKE Y,TAKAKI A,IWASAKI Y,et al. Meta-analysis:Interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma[J]. J Viral Hepat,2010,17(4):287-292.
|
|
[26] HSU YC,HO HJ,WU MS,et al. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma[J]. Hepatology,2013,58(1):150-157.
|
|
[27] NAGAOKI Y,IMAMURA M,NISHIDA Y,et al. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma:Comparison with interferon-based therapy[J]. J Med Virol,2019,91(4):650-658.
|
|
[28] MINAMI T,TATEISHI R,NAKAGOMI R,et al. The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma[J]. J Hepatol,2016,65(6):1272-1273.
|
|
[29] WAZIRY R,HAJARIZADEH B,GREBELY J,et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy:A systematic review,meta-analyses,and meta-regression[J]. J Hepatol,2017,67(6):1204-1212.
|
|
[30] SPAAN M,van OORD G,KREEFFT K,et al. Immunological analysis during interferon-free therapy for chronic hepatitis C virus infection reveals modulation of the natural killer cell compartment[J]. J Infect Dis,2016,213(2):216-223.
|
|
[31] SERTI E,CHEPA-LOTREA X,KIM YJ,et al. Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function[J]. Gastroenterology,2015,149(1):190-200.
|
|
[32] VILLANI R,FACCIORUSSO A,BELLANTI F,et al. DAAs rapidly reduce inflammation but increase serum VEGF level:A rationale for tumor risk during Anti-HCV treatment[J]. PLo S One,2016,11(12):e0167934.
|
|
[33] LLOVET JM,VILLANUEVA A. Liver cancer:Effect of HCV clearance with direct-acting antiviral agents on HCC[J]. Nat Rev Gastroenterol Hepatol,2016,13(10):561-562.
|
|
[34] SINGH S,NAUTIYAL A,LOKE YK. Oral direct-acting antivirals and the incidence or recurrence of hepatocellular carcinoma:A systematic review and meta-analysis[J]. Frontline Gastroenterol,2018,9(4):262-270.
|
|
[35] GRIFFITH AS,HAYASHI PH,BURKE LM,et al. Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response:Unlocking the potential of T-cell-mediated immunosurveillance[J]. J Hepatocell Carcinoma,2018,5:55-59.
|
|
[36] MARTIN B,HENNECKE N,LOHMANN V,et al. Restoration of HCV-specific CD8+T cell function by interferon-free therapy[J]. J Hepatol,2014,61(3):538-543.
|
DownLoad: